Literature DB >> 16580235

Haemoglobin A1c (HbA1C) in non-diabetic and diabetic vascular patients. Is HbA1C an independent risk factor and predictor of adverse outcome?

C J O'Sullivan1, N Hynes, B Mahendran, E J Andrews, G Avalos, S Tawfik, A Lowery, S Sultan.   

Abstract

BACKGROUND: Plasma Haemoglobin A1c (HbA1c) reflects ambient mean glycaemia over a 2-3 months period. Reports indicate that patients, with and without diabetes, with an elevated HbA1c have an increased risk of adverse outcome following surgical intervention. Our aim was to determine whether elevated plasma HbA1c level was associated with increased postoperative morbidity and mortality in patients undergoing vascular surgical procedures.
METHODS: Plasma HbA1c was measured prospectively in 165 consecutive patients undergoing emergency and elective vascular surgical procedures over a 6-month period. Patients were categorized into four groups depending on whether their plasma HbA1c was < or =6%, 6.1-7%, 7.1-8% or >8% and clinical data was entered into a prospectively maintained database. Patients were also classified by diabetic status with suboptimal HbA1c in a patient without diabetes being >6 to < or =7% and suboptimal HbA1c in a patient with diabetes being >7%. Patients with plasma HbA1c >7% were reclassified as having undiagnosed diabetes mellitus. Composite primary endpoints were all cause 30-day morbidity and mortality and all cause 6-month mortality. Composite secondary endpoints were procedure specific complications, adverse cardiac events, stroke, infection and mean length of hospital stay.
RESULTS: Of the 165 patients studied, 43 (26.1%) had diabetes and the remaining 122 (73.9%) did not. The mean age was 72 years and 59% were male. Suboptimal HbA1c levels were found in 58% patients without diabetes and in 51% patients with diabetes. In patients without diabetes those with suboptimal HbA1c levels (6-7%) had a significantly higher incidence of overall 30-day morbidity compared to patients with HbA1c levels < or =6% (56.5 vs 15.7%, p<0.001). Similarly, for patients with diabetes those with suboptimal HbA1c levels (HbA1c >7%) had a significantly higher incidence of 30-day morbidity compared to those with HbA1c levels < or =7% (59.1% vs 19%, p=0.018). Multivariate analysis revealed that a plasma HbA1c level of >6 to < or =7% was a significant independent predictor of overall 30-day morbidity in patients without diabetes undergoing vascular surgical procedures. No difference in mortality, composite secondary endpoints, procedure specific complications, stroke or mean length of hospital stay was observed between any of the groups in the study.
CONCLUSION: Suboptimal HbA1c levels may hold prognostic significance in patients without diabetes undergoing vascular surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580235     DOI: 10.1016/j.ejvs.2006.01.011

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  40 in total

1.  Assessing inpatient glycemic control: what are the next steps?

Authors:  Curtiss B Cook; Kay E Wellik; Gail L Kongable; Jianfen Shu
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

Review 2.  Association of Elevated Pre-operative Hemoglobin A1c and Post-operative Complications in Non-diabetic Patients: A Systematic Review.

Authors:  Negar Karimian; Petru Niculiseanu; Alexandre Amar-Zifkin; Francesco Carli; Liane S Feldman
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

Review 3.  Perioperative Management of Diabetes Mellitus: Novel Approaches.

Authors:  Nadine E Palermo; Rajesh Garg
Journal:  Curr Diab Rep       Date:  2019-02-26       Impact factor: 4.810

4.  Diabetes does not influence selected clinical outcomes in critically ill burn patients.

Authors:  Chaitanya K Dahagam; Alejandra Mora; Steven E Wolf; Charles E Wade
Journal:  J Burn Care Res       Date:  2011 Mar-Apr       Impact factor: 1.845

5.  Update on a Quality Initiative to Standardize Perioperative Care for Continuous Subcutaneous Insulin Infusion Therapy.

Authors:  Patricia A Mackey; Bithika M Thompson; Mary E Boyle; Heidi A Apsey; Karen M Seifert; Richard T Schlinkert; Joshua D Stearns; Curtiss B Cook
Journal:  J Diabetes Sci Technol       Date:  2015-06-19

6.  Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts.

Authors:  R Santos-Oliveira; C Purdy; M Pereira da Silva; A M dos Anjos Carneiro-Leão; M Machado; T R Einarson
Journal:  Diabetologia       Date:  2011-02-22       Impact factor: 10.122

Review 7.  Glucometrics and Insulinometrics.

Authors:  Bithika M Thompson; Curtiss B Cook
Journal:  Curr Diab Rep       Date:  2017-10-23       Impact factor: 4.810

8.  Association of elevated fasting glucose with lower patency and increased major adverse limb events among patients with diabetes undergoing infrapopliteal balloon angioplasty.

Authors:  Satinder Singh; Ehrin J Armstrong; Walid Sherif; Bejan Alvandi; Gregory G Westin; Gagan D Singh; Ezra A Amsterdam; John R Laird
Journal:  Vasc Med       Date:  2014-06-17       Impact factor: 3.239

9.  Patterns of changes in fasting plasma glucose, hemoglobin A1c and the area under the curve during oral glucose tolerance tests in prediabetic subjects: results from a 16-year prospective cohort study among first-degree relatives of type 2 diabetic patients.

Authors:  Shahla Safari; Masoud Amini; Ashraf Aminorroaya; Awat Feizi
Journal:  Acta Diabetol       Date:  2020-10-21       Impact factor: 4.280

10.  Delta-glycated hemoglobin: a novel independent risk factor for cardiovascular events in patients without diabetes mellitus.

Authors:  H Diedrichs; R Pfister; Z Clement; J Hagemeister; C A Schneider
Journal:  J Endocrinol Invest       Date:  2009-06-15       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.